Radiation-Free option for Low-Risk breast cancer?
NCT ID NCT02400190
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This study follows 202 postmenopausal women with early-stage, hormone-sensitive breast cancer who choose to skip radiation after lumpectomy and take only hormone therapy. Researchers track cancer recurrence over 10 years to see if this approach is safe for this low-risk group. The goal is to gather evidence that might spare future patients from unnecessary radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
East Carolina University
Greenville, North Carolina, 27853, United States
-
Harvard University
Cambridge, Massachusetts, 02138, United States
-
Johns Hopkins University
Baltimore, Maryland, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Stanford University
Stanford, California, 94305, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
endocrine therapy alone without radiotherapy
What this could lead to
If successful, this could show that carefully selected patients can avoid radiation and its side effects without increasing cancer recurrence risk.
What could go wrong
This is an observational study, not a treatment trial. It only tracks outcomes in a very specific, low-risk group, so results may not apply to most breast cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.